Available Stat

Yes

Performing Lab

Parnassus, Mission Bay & Mt. Zion Hematology
Berkeley Outpatient Center

Performed

Parnassus, Mission Bay & Mt. Zion Hematology: 24-hours per day, 7-days per week
Berkeley Outpatient Center: Test available Mon-Fri (0800-1630)
 

Methodology

Mechanical clot detection

Reported

STAT 1 hour, Routine 4 hours

Additional Information

Current reagents permit the reporting of results up to 100 seconds; if no clot is detected by that time the result will be reported as > 100 seconds.

Per in-house study done 1/2023, the sensitivity of the PTT for detecting factor deficiencies is as follows:
     Factor VIII level may prolong the PTT when < 39%
     Factor IX level may prolong the PTT when < 21%
     Factor XI level may prolong the PTT when < 31%

Therapeutic anticoagulation with unfractionated heparin is generally monitored with the PTT. Direct oral anticoagulant medications (non-vitamin K) should not be monitored with PT/INR or aPTT because the effect of these tests is not predictable. Recommendations for monitoring anticoagulant medications are available through the UCSF Hematology consultation services: for adults, pager 443-4276, for pediatrics pager 443-6966.

Patients with lupus anticoagulants being treated with unfractionated heparin are usually monitored with anti-Xa (heparin level), rather than with the PTT. Therapeutic anticoagulation with intravenous direct thrombin inhibitors (i.e. argatroban, bivalirudin) is generally monitored with the PTT. Recommendations for therapy and monitoring are available through the Hematology Consultation services.

For patients not being treated with heparin for whom a sample may be contaminated with heparin, a heparin-neutralizing enzyme can be employed to overcome the effect of up to 2U/mL of unfractionated heparin/mL. Heparin neutralization is not available at Parnassus or Mt. Zion. At Mission Bay, performance of an aPTT after heparin neutralization may rarely be necessary for care of pediatric patients, and is subject to approval by laboratory medicine resident or faculty. In these rare circumstances, heparin neutralization may detect a substantial unexpected coagulopathy when a sample is drawn through a heparinized line. Of note, heparin neutralization reduces coagulation factor levels (typically by approximately 10%, but up to a 30% decrease can occur; internal UCSF study, Jan & Apr 2013). Therefore, heparin neutralization should not be used to detect slight abnormalities of coagulation, small changes in clotting times, or when monitoring anticoagulation.

Synonyms

  • PTT
  • aPTT
  • Monitoring Anticoagulation
  • Monitoring heparin

Sample Type

Citrated plasma

Collect

Blue (2.7 mL) or Lt. Blue (1.8 mL) top filled to full extent of vacuum

Amount to Collect

Blue top: 2.7 mL blood
Lt. Blue top: 1.8 mL blood

Note: If Hepzyme is required draw a full Blue top (2.7 mL) (available at Mission Bay only)

Preferred Volume

1.5 mL plasma

Minimum Volume

1 mL plasma

Remarks

1. Check the expiration date on the label of the blue top vacutainer before drawing the patient.
2. For blood collection in a sodium citrate blue top, the tube must be filled to above the Minimum Fill Indicator on the tube. It is crucial to wait and allow the tube to stop filling before removing it from the needle.
3. With use of a butterfly needle, draw about 1 cc using a separate blue top to remove air from tubing, discard the first tube and then draw a second blue top tube filled to the full extent of the vacuum.
4. Tubes should not be filled past the Maximum Fill dashed line by either using a syringe or removing the tube cap.

For patients with Hct's >= 55% please contact Hematology (For Parnassus patients call 3-1747, for Mission Bay patients call 6-0194) to obtain blue top tubes with adjusted citrate volumes in order to maintain the proper citrate to plasma ratio for coagulation studies.

Stability (from collection to initiation)

If the patient is not on heparin, unopened, uncentrifuged specimens are stable for up to 4 hours at room or refrigerator temperature. If the patient is on un-fractionated heparin, the plasma should be separated within one hour and tested within four hours of collection. Plasma may be frozen at -20C if PTT testing must be delayed, but results may be slightly affected.

Unacceptable Conditions

Samples collected in outdated blue top vacutainer. Over-filled or under-filled tubes may be rejected

Test Code

PTT

Performing Lab

Parnassus, Mission Bay & Mt. Zion Hematology
Berkeley Outpatient Center

Preferred Volume

1.5 mL plasma

Minimum Volume

1 mL plasma

Unacceptable Conditions

Samples collected in outdated blue top vacutainer. Over-filled or under-filled tubes may be rejected

Stability (from collection to initiation)

If the patient is not on heparin, unopened, uncentrifuged specimens are stable for up to 4 hours at room or refrigerator temperature. If the patient is on un-fractionated heparin, the plasma should be separated within one hour and tested within four hours of collection. Plasma may be frozen at -20C if PTT testing must be delayed, but results may be slightly affected.

Units

seconds

Reference Interval

Age Normal range
Full term infant, 0-5 day old 25.0-60.0 seconds
Full term infant, 6 days-3 months 24.0-50.0 seconds
>3 months 21.6 - 30.8 seconds

An infant reference range has not been experimentally determined using our current PTT reagent. The PTTs of normal infants are longer than those of adults due to lower factor levels in the first months of life; the infant reference ranges provided (5 days, 3 months) are based on published literature (Ref: Andrew M et al. Blood 1987; 70-165). This publication further indicates that although trending longer, PTT values at 3 months may not differ statistically from adult values. If there is concern for clotting factor deficiency or inhibitor in an infant, factor activity assays should be requested if clinically indicated.

Critical Values

>= 60 seconds if new finding within previous 24 hours. >= 80 seconds are always phoned

Additional Information

Current reagents permit the reporting of results up to 100 seconds; if no clot is detected by that time the result will be reported as > 100 seconds.

Per in-house study done 1/2023, the sensitivity of the PTT for detecting factor deficiencies is as follows:
     Factor VIII level may prolong the PTT when < 39%
     Factor IX level may prolong the PTT when < 21%
     Factor XI level may prolong the PTT when < 31%

Therapeutic anticoagulation with unfractionated heparin is generally monitored with the PTT. Direct oral anticoagulant medications (non-vitamin K) should not be monitored with PT/INR or aPTT because the effect of these tests is not predictable. Recommendations for monitoring anticoagulant medications are available through the UCSF Hematology consultation services: for adults, pager 443-4276, for pediatrics pager 443-6966.

Patients with lupus anticoagulants being treated with unfractionated heparin are usually monitored with anti-Xa (heparin level), rather than with the PTT. Therapeutic anticoagulation with intravenous direct thrombin inhibitors (i.e. argatroban, bivalirudin) is generally monitored with the PTT. Recommendations for therapy and monitoring are available through the Hematology Consultation services.

For patients not being treated with heparin for whom a sample may be contaminated with heparin, a heparin-neutralizing enzyme can be employed to overcome the effect of up to 2U/mL of unfractionated heparin/mL. Heparin neutralization is not available at Parnassus or Mt. Zion. At Mission Bay, performance of an aPTT after heparin neutralization may rarely be necessary for care of pediatric patients, and is subject to approval by laboratory medicine resident or faculty. In these rare circumstances, heparin neutralization may detect a substantial unexpected coagulopathy when a sample is drawn through a heparinized line. Of note, heparin neutralization reduces coagulation factor levels (typically by approximately 10%, but up to a 30% decrease can occur; internal UCSF study, Jan & Apr 2013). Therefore, heparin neutralization should not be used to detect slight abnormalities of coagulation, small changes in clotting times, or when monitoring anticoagulation.

CPT Codes

85730

LDT or Modified FDA

Yes

LOINC Codes

3173-2

Available Stat

Yes

Test Code

PTT

Performing Lab

Parnassus, Mission Bay & Mt. Zion Hematology
Berkeley Outpatient Center

Performed

Parnassus, Mission Bay & Mt. Zion Hematology: 24-hours per day, 7-days per week
Berkeley Outpatient Center: Test available Mon-Fri (0800-1630)
 

Methodology

Mechanical clot detection

Remarks

1. Check the expiration date on the label of the blue top vacutainer before drawing the patient.
2. For blood collection in a sodium citrate blue top, the tube must be filled to above the Minimum Fill Indicator on the tube. It is crucial to wait and allow the tube to stop filling before removing it from the needle.
3. With use of a butterfly needle, draw about 1 cc using a separate blue top to remove air from tubing, discard the first tube and then draw a second blue top tube filled to the full extent of the vacuum.
4. Tubes should not be filled past the Maximum Fill dashed line by either using a syringe or removing the tube cap.

For patients with Hct's >= 55% please contact Hematology (For Parnassus patients call 3-1747, for Mission Bay patients call 6-0194) to obtain blue top tubes with adjusted citrate volumes in order to maintain the proper citrate to plasma ratio for coagulation studies.

Collect

Blue (2.7 mL) or Lt. Blue (1.8 mL) top filled to full extent of vacuum

Amount to Collect

Blue top: 2.7 mL blood
Lt. Blue top: 1.8 mL blood

Note: If Hepzyme is required draw a full Blue top (2.7 mL) (available at Mission Bay only)

Sample Type

Citrated plasma

Preferred Volume

1.5 mL plasma

Minimum Volume

1 mL plasma

Unacceptable Conditions

Samples collected in outdated blue top vacutainer. Over-filled or under-filled tubes may be rejected

Units

seconds

Reference Interval

Age Normal range
Full term infant, 0-5 day old 25.0-60.0 seconds
Full term infant, 6 days-3 months 24.0-50.0 seconds
>3 months 21.6 - 30.8 seconds

An infant reference range has not been experimentally determined using our current PTT reagent. The PTTs of normal infants are longer than those of adults due to lower factor levels in the first months of life; the infant reference ranges provided (5 days, 3 months) are based on published literature (Ref: Andrew M et al. Blood 1987; 70-165). This publication further indicates that although trending longer, PTT values at 3 months may not differ statistically from adult values. If there is concern for clotting factor deficiency or inhibitor in an infant, factor activity assays should be requested if clinically indicated.

Critical Values

>= 60 seconds if new finding within previous 24 hours. >= 80 seconds are always phoned

Synonyms

  • PTT
  • aPTT
  • Monitoring Anticoagulation
  • Monitoring heparin

Stability (from collection to initiation)

If the patient is not on heparin, unopened, uncentrifuged specimens are stable for up to 4 hours at room or refrigerator temperature. If the patient is on un-fractionated heparin, the plasma should be separated within one hour and tested within four hours of collection. Plasma may be frozen at -20C if PTT testing must be delayed, but results may be slightly affected.

Reported

STAT 1 hour, Routine 4 hours

Additional Information

Current reagents permit the reporting of results up to 100 seconds; if no clot is detected by that time the result will be reported as > 100 seconds.

Per in-house study done 1/2023, the sensitivity of the PTT for detecting factor deficiencies is as follows:
     Factor VIII level may prolong the PTT when < 39%
     Factor IX level may prolong the PTT when < 21%
     Factor XI level may prolong the PTT when < 31%

Therapeutic anticoagulation with unfractionated heparin is generally monitored with the PTT. Direct oral anticoagulant medications (non-vitamin K) should not be monitored with PT/INR or aPTT because the effect of these tests is not predictable. Recommendations for monitoring anticoagulant medications are available through the UCSF Hematology consultation services: for adults, pager 443-4276, for pediatrics pager 443-6966.

Patients with lupus anticoagulants being treated with unfractionated heparin are usually monitored with anti-Xa (heparin level), rather than with the PTT. Therapeutic anticoagulation with intravenous direct thrombin inhibitors (i.e. argatroban, bivalirudin) is generally monitored with the PTT. Recommendations for therapy and monitoring are available through the Hematology Consultation services.

For patients not being treated with heparin for whom a sample may be contaminated with heparin, a heparin-neutralizing enzyme can be employed to overcome the effect of up to 2U/mL of unfractionated heparin/mL. Heparin neutralization is not available at Parnassus or Mt. Zion. At Mission Bay, performance of an aPTT after heparin neutralization may rarely be necessary for care of pediatric patients, and is subject to approval by laboratory medicine resident or faculty. In these rare circumstances, heparin neutralization may detect a substantial unexpected coagulopathy when a sample is drawn through a heparinized line. Of note, heparin neutralization reduces coagulation factor levels (typically by approximately 10%, but up to a 30% decrease can occur; internal UCSF study, Jan & Apr 2013). Therefore, heparin neutralization should not be used to detect slight abnormalities of coagulation, small changes in clotting times, or when monitoring anticoagulation.

CPT Codes

85730

LDT or Modified FDA

Yes

LOINC Codes

3173-2
Ordering

Available Stat

Yes

Performing Lab

Parnassus, Mission Bay & Mt. Zion Hematology
Berkeley Outpatient Center

Performed

Parnassus, Mission Bay & Mt. Zion Hematology: 24-hours per day, 7-days per week
Berkeley Outpatient Center: Test available Mon-Fri (0800-1630)
 

Methodology

Mechanical clot detection

Reported

STAT 1 hour, Routine 4 hours

Additional Information

Current reagents permit the reporting of results up to 100 seconds; if no clot is detected by that time the result will be reported as > 100 seconds.

Per in-house study done 1/2023, the sensitivity of the PTT for detecting factor deficiencies is as follows:
     Factor VIII level may prolong the PTT when < 39%
     Factor IX level may prolong the PTT when < 21%
     Factor XI level may prolong the PTT when < 31%

Therapeutic anticoagulation with unfractionated heparin is generally monitored with the PTT. Direct oral anticoagulant medications (non-vitamin K) should not be monitored with PT/INR or aPTT because the effect of these tests is not predictable. Recommendations for monitoring anticoagulant medications are available through the UCSF Hematology consultation services: for adults, pager 443-4276, for pediatrics pager 443-6966.

Patients with lupus anticoagulants being treated with unfractionated heparin are usually monitored with anti-Xa (heparin level), rather than with the PTT. Therapeutic anticoagulation with intravenous direct thrombin inhibitors (i.e. argatroban, bivalirudin) is generally monitored with the PTT. Recommendations for therapy and monitoring are available through the Hematology Consultation services.

For patients not being treated with heparin for whom a sample may be contaminated with heparin, a heparin-neutralizing enzyme can be employed to overcome the effect of up to 2U/mL of unfractionated heparin/mL. Heparin neutralization is not available at Parnassus or Mt. Zion. At Mission Bay, performance of an aPTT after heparin neutralization may rarely be necessary for care of pediatric patients, and is subject to approval by laboratory medicine resident or faculty. In these rare circumstances, heparin neutralization may detect a substantial unexpected coagulopathy when a sample is drawn through a heparinized line. Of note, heparin neutralization reduces coagulation factor levels (typically by approximately 10%, but up to a 30% decrease can occur; internal UCSF study, Jan & Apr 2013). Therefore, heparin neutralization should not be used to detect slight abnormalities of coagulation, small changes in clotting times, or when monitoring anticoagulation.

Synonyms

  • PTT
  • aPTT
  • Monitoring Anticoagulation
  • Monitoring heparin
Collection

Sample Type

Citrated plasma

Collect

Blue (2.7 mL) or Lt. Blue (1.8 mL) top filled to full extent of vacuum

Amount to Collect

Blue top: 2.7 mL blood
Lt. Blue top: 1.8 mL blood

Note: If Hepzyme is required draw a full Blue top (2.7 mL) (available at Mission Bay only)

Preferred Volume

1.5 mL plasma

Minimum Volume

1 mL plasma

Remarks

1. Check the expiration date on the label of the blue top vacutainer before drawing the patient.
2. For blood collection in a sodium citrate blue top, the tube must be filled to above the Minimum Fill Indicator on the tube. It is crucial to wait and allow the tube to stop filling before removing it from the needle.
3. With use of a butterfly needle, draw about 1 cc using a separate blue top to remove air from tubing, discard the first tube and then draw a second blue top tube filled to the full extent of the vacuum.
4. Tubes should not be filled past the Maximum Fill dashed line by either using a syringe or removing the tube cap.

For patients with Hct's >= 55% please contact Hematology (For Parnassus patients call 3-1747, for Mission Bay patients call 6-0194) to obtain blue top tubes with adjusted citrate volumes in order to maintain the proper citrate to plasma ratio for coagulation studies.

Stability (from collection to initiation)

If the patient is not on heparin, unopened, uncentrifuged specimens are stable for up to 4 hours at room or refrigerator temperature. If the patient is on un-fractionated heparin, the plasma should be separated within one hour and tested within four hours of collection. Plasma may be frozen at -20C if PTT testing must be delayed, but results may be slightly affected.

Unacceptable Conditions

Samples collected in outdated blue top vacutainer. Over-filled or under-filled tubes may be rejected
Processing

Test Code

PTT

Performing Lab

Parnassus, Mission Bay & Mt. Zion Hematology
Berkeley Outpatient Center

Preferred Volume

1.5 mL plasma

Minimum Volume

1 mL plasma

Unacceptable Conditions

Samples collected in outdated blue top vacutainer. Over-filled or under-filled tubes may be rejected

Stability (from collection to initiation)

If the patient is not on heparin, unopened, uncentrifuged specimens are stable for up to 4 hours at room or refrigerator temperature. If the patient is on un-fractionated heparin, the plasma should be separated within one hour and tested within four hours of collection. Plasma may be frozen at -20C if PTT testing must be delayed, but results may be slightly affected.
Result Interpretation

Units

seconds

Reference Interval

Age Normal range
Full term infant, 0-5 day old 25.0-60.0 seconds
Full term infant, 6 days-3 months 24.0-50.0 seconds
>3 months 21.6 - 30.8 seconds

An infant reference range has not been experimentally determined using our current PTT reagent. The PTTs of normal infants are longer than those of adults due to lower factor levels in the first months of life; the infant reference ranges provided (5 days, 3 months) are based on published literature (Ref: Andrew M et al. Blood 1987; 70-165). This publication further indicates that although trending longer, PTT values at 3 months may not differ statistically from adult values. If there is concern for clotting factor deficiency or inhibitor in an infant, factor activity assays should be requested if clinically indicated.

Critical Values

>= 60 seconds if new finding within previous 24 hours. >= 80 seconds are always phoned

Additional Information

Current reagents permit the reporting of results up to 100 seconds; if no clot is detected by that time the result will be reported as > 100 seconds.

Per in-house study done 1/2023, the sensitivity of the PTT for detecting factor deficiencies is as follows:
     Factor VIII level may prolong the PTT when < 39%
     Factor IX level may prolong the PTT when < 21%
     Factor XI level may prolong the PTT when < 31%

Therapeutic anticoagulation with unfractionated heparin is generally monitored with the PTT. Direct oral anticoagulant medications (non-vitamin K) should not be monitored with PT/INR or aPTT because the effect of these tests is not predictable. Recommendations for monitoring anticoagulant medications are available through the UCSF Hematology consultation services: for adults, pager 443-4276, for pediatrics pager 443-6966.

Patients with lupus anticoagulants being treated with unfractionated heparin are usually monitored with anti-Xa (heparin level), rather than with the PTT. Therapeutic anticoagulation with intravenous direct thrombin inhibitors (i.e. argatroban, bivalirudin) is generally monitored with the PTT. Recommendations for therapy and monitoring are available through the Hematology Consultation services.

For patients not being treated with heparin for whom a sample may be contaminated with heparin, a heparin-neutralizing enzyme can be employed to overcome the effect of up to 2U/mL of unfractionated heparin/mL. Heparin neutralization is not available at Parnassus or Mt. Zion. At Mission Bay, performance of an aPTT after heparin neutralization may rarely be necessary for care of pediatric patients, and is subject to approval by laboratory medicine resident or faculty. In these rare circumstances, heparin neutralization may detect a substantial unexpected coagulopathy when a sample is drawn through a heparinized line. Of note, heparin neutralization reduces coagulation factor levels (typically by approximately 10%, but up to a 30% decrease can occur; internal UCSF study, Jan & Apr 2013). Therefore, heparin neutralization should not be used to detect slight abnormalities of coagulation, small changes in clotting times, or when monitoring anticoagulation.
Administrative

CPT Codes

85730

LDT or Modified FDA

Yes

LOINC Codes

3173-2
Complete View

Available Stat

Yes

Test Code

PTT

Performing Lab

Parnassus, Mission Bay & Mt. Zion Hematology
Berkeley Outpatient Center

Performed

Parnassus, Mission Bay & Mt. Zion Hematology: 24-hours per day, 7-days per week
Berkeley Outpatient Center: Test available Mon-Fri (0800-1630)
 

Methodology

Mechanical clot detection

Remarks

1. Check the expiration date on the label of the blue top vacutainer before drawing the patient.
2. For blood collection in a sodium citrate blue top, the tube must be filled to above the Minimum Fill Indicator on the tube. It is crucial to wait and allow the tube to stop filling before removing it from the needle.
3. With use of a butterfly needle, draw about 1 cc using a separate blue top to remove air from tubing, discard the first tube and then draw a second blue top tube filled to the full extent of the vacuum.
4. Tubes should not be filled past the Maximum Fill dashed line by either using a syringe or removing the tube cap.

For patients with Hct's >= 55% please contact Hematology (For Parnassus patients call 3-1747, for Mission Bay patients call 6-0194) to obtain blue top tubes with adjusted citrate volumes in order to maintain the proper citrate to plasma ratio for coagulation studies.

Collect

Blue (2.7 mL) or Lt. Blue (1.8 mL) top filled to full extent of vacuum

Amount to Collect

Blue top: 2.7 mL blood
Lt. Blue top: 1.8 mL blood

Note: If Hepzyme is required draw a full Blue top (2.7 mL) (available at Mission Bay only)

Sample Type

Citrated plasma

Preferred Volume

1.5 mL plasma

Minimum Volume

1 mL plasma

Unacceptable Conditions

Samples collected in outdated blue top vacutainer. Over-filled or under-filled tubes may be rejected

Units

seconds

Reference Interval

Age Normal range
Full term infant, 0-5 day old 25.0-60.0 seconds
Full term infant, 6 days-3 months 24.0-50.0 seconds
>3 months 21.6 - 30.8 seconds

An infant reference range has not been experimentally determined using our current PTT reagent. The PTTs of normal infants are longer than those of adults due to lower factor levels in the first months of life; the infant reference ranges provided (5 days, 3 months) are based on published literature (Ref: Andrew M et al. Blood 1987; 70-165). This publication further indicates that although trending longer, PTT values at 3 months may not differ statistically from adult values. If there is concern for clotting factor deficiency or inhibitor in an infant, factor activity assays should be requested if clinically indicated.

Critical Values

>= 60 seconds if new finding within previous 24 hours. >= 80 seconds are always phoned

Synonyms

  • PTT
  • aPTT
  • Monitoring Anticoagulation
  • Monitoring heparin

Stability (from collection to initiation)

If the patient is not on heparin, unopened, uncentrifuged specimens are stable for up to 4 hours at room or refrigerator temperature. If the patient is on un-fractionated heparin, the plasma should be separated within one hour and tested within four hours of collection. Plasma may be frozen at -20C if PTT testing must be delayed, but results may be slightly affected.

Reported

STAT 1 hour, Routine 4 hours

Additional Information

Current reagents permit the reporting of results up to 100 seconds; if no clot is detected by that time the result will be reported as > 100 seconds.

Per in-house study done 1/2023, the sensitivity of the PTT for detecting factor deficiencies is as follows:
     Factor VIII level may prolong the PTT when < 39%
     Factor IX level may prolong the PTT when < 21%
     Factor XI level may prolong the PTT when < 31%

Therapeutic anticoagulation with unfractionated heparin is generally monitored with the PTT. Direct oral anticoagulant medications (non-vitamin K) should not be monitored with PT/INR or aPTT because the effect of these tests is not predictable. Recommendations for monitoring anticoagulant medications are available through the UCSF Hematology consultation services: for adults, pager 443-4276, for pediatrics pager 443-6966.

Patients with lupus anticoagulants being treated with unfractionated heparin are usually monitored with anti-Xa (heparin level), rather than with the PTT. Therapeutic anticoagulation with intravenous direct thrombin inhibitors (i.e. argatroban, bivalirudin) is generally monitored with the PTT. Recommendations for therapy and monitoring are available through the Hematology Consultation services.

For patients not being treated with heparin for whom a sample may be contaminated with heparin, a heparin-neutralizing enzyme can be employed to overcome the effect of up to 2U/mL of unfractionated heparin/mL. Heparin neutralization is not available at Parnassus or Mt. Zion. At Mission Bay, performance of an aPTT after heparin neutralization may rarely be necessary for care of pediatric patients, and is subject to approval by laboratory medicine resident or faculty. In these rare circumstances, heparin neutralization may detect a substantial unexpected coagulopathy when a sample is drawn through a heparinized line. Of note, heparin neutralization reduces coagulation factor levels (typically by approximately 10%, but up to a 30% decrease can occur; internal UCSF study, Jan & Apr 2013). Therefore, heparin neutralization should not be used to detect slight abnormalities of coagulation, small changes in clotting times, or when monitoring anticoagulation.

CPT Codes

85730

LDT or Modified FDA

Yes

LOINC Codes

3173-2

×
Learn More Remind Me Later Dismiss